Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events.
Blinatumomab, a CD19/CD3 bispecific T-cell engager (BiTE®) immuno-oncology therapy for the treatment of B-cell malignancies, is associated with neurologic adverse events in a subgroup of patients. Here we provide evidence for a two-step process for the development of neurologic adverse events in response to blinatumomab: 1) blinatumomab induced B-cell-independent redistribution of peripheral T cells, including T-cell adhesion to blood vessel endothelium, endothelial activation, and T-cell transmigration into the perivascular space, where 2) blinatumomab induced B-cell-dependent T-cell activation and cytokine release to potentially trigger neurologic adverse events. Evidence for this process includes the coincidence of T-cell redistribution and the early occurrence of most neurologic adverse events; T-cell transmigration through brain microvascular endothelium; detection of T cells, B cells, and blinatumomab in cerebrospinal fluid; blinatumomab-induced T-cell rolling and adhesion to vascular endothelial cells in vitro; and the ability of anti-adhesive agents to interfere with blinatumomab-induced interactions between T cells and vascular endothelial cells in vitro and in patients. Based on these observations, we propose a model that could be the basis of mitigation strategies for neurologic adverse events associated with blinatumomab treatment and other T-cell therapies.